Upstream Bio to present novel data on verekitug's potency at EAACI Congress 2025, targeting respiratory inflammatory diseases.
Quiver AI Summary
Upstream Bio, Inc., a clinical-stage company focused on treatments for inflammatory diseases, will present at the EAACI Congress 2025 in Glasgow on June 15, 2025. The presentation will showcase pharmacology modeling data supporting the efficacy of veroikitug, an antibody targeting the TSLP receptor, compared to existing methods that target the TSLP ligand. TSLP plays a significant role in allergic and inflammatory responses, making its receptor an attractive target for therapies across various conditions, including asthma. Upstream Bio is conducting multiple Phase 2 clinical trials for verekitug in severe asthma, chronic rhinosinusitis, and is initiating a trial for chronic obstructive pulmonary disease. The company emphasizes the potential of verekitug to address unmet needs in inflammatory disease treatment.
Potential Positives
- Upstream Bio is presenting at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, which highlights the company's commitment to disseminating important research and gaining visibility in the field of inflammatory diseases.
- The presentation of data supporting verekitug's mechanism for greater potency against TSLP receptor targeting may enhance the perceived efficacy and competitive advantage of the treatment in comparison to existing therapies.
- Verekitug is the only monoclonal antibody currently in clinical development targeting the TSLP receptor, positioning Upstream Bio uniquely in the market and potentially leading to significant differentiation from competitors.
- The ongoing Phase 2 clinical trials in severe asthma, chronic rhinosinusitis with nasal polyps, and initiation of trials in chronic obstructive pulmonary disease demonstrate Upstream Bio’s proactive approach in expanding the application of verekitug across multiple serious conditions, which may capture a broader patient base and market opportunity.
Potential Negatives
- The press release contains several forward-looking statements, indicating potential risks and uncertainties surrounding the clinical development and commercialization of verekitug, which could lead to significantly delayed or failed product launches.
- There is a heavy reliance on third parties for conducting clinical trials and manufacturing verekitug, which poses a risk to the company’s control over the development process and timelines.
- Upstream Bio's need for substantial additional funding to complete development activities raises concerns about its financial stability and ability to navigate the competitive landscape effectively.
FAQ
What is Upstream Bio presenting at the EAACI Congress 2025?
Upstream Bio will present data on TSLP receptor targeting with verekitug, highlighting its greater potency compared to existing treatments.
When is the presentation scheduled?
The presentation is scheduled for Sunday, June 15, 2025, from 12:45 to 13:45 BST.
What is verekitug?
Verekitug is a monoclonal antibody targeting the TSLP receptor, currently in clinical trials for severe respiratory disorders.
How does blocking TSLP signaling help patients?
Blocking TSLP signaling may alleviate inflammatory responses associated with allergic diseases like asthma and chronic rhinosinusitis.
What trials is verekitug currently involved in?
Verekitug is in ongoing Phase 2 trials for severe asthma, chronic rhinosinusitis with nasal polyps, and initiating in COPD.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
Full Release
WALTHAM, Mass., June 05, 2025 (GLOBE NEWSWIRE) --
Upstream Bio, Inc.
(Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced an upcoming presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 in Glasgow, UK, on Sunday, June 15, 2025. The presentation features translational pharmacology modeling data that supports Thymic Stromal Lymphopoietin (TSLP) receptor targeting with verekitug as a mechanism for greater potency when compared to treatment approaches that target the TSLP ligand.
Presentation details:
Presentation Title:
In silico system pharmacology modeling provides insights into a mechanism for greater potency of TSLP/TSLPR pathway inhibition with verekitug, a novel antibody antagonist of the TSLP receptor, as compared with tezepelumab
Presenting Author:
Ashish Kalra, PhD, Vice President, Translational Research, Upstream Bio
Poster Number:
D3.113
Session:
TPS55 – Asthma 06
Presentation Date and Time:
Sunday, June 15, 2025 – 12:45 - 13:45 BST
About TSLP and TSLPR Blockade
Thymic Stromal Lymphopoietin (TSLP) is a cytokine that is a key driver of the inflammatory response in major allergic and inflammatory diseases, such as asthma, where disruption of TSLP signaling has been clinically validated as an effective therapeutic strategy.
TSLP activation is one of the first events in the inflammatory cascade stimulated by allergens, viruses and other triggers, initiating the activation of downstream targets such as IL-4, IL-5, IL-13, IL-17 and IgE. Because TSLP is a target upstream in the inflammatory cascade, blocking the TSLP receptor (TSLPR) presents an opportunity for a single treatment to impact the drivers of multiple pathological inflammatory processes across a broad set of diseases.
About Verekitug
Verekitug is a novel recombinant fully human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that binds to the TSLP receptor and inhibits proinflammatory signaling initiated by TSLP. It is the only monoclonal antibody currently in clinical development that targets and inhibits the TSLP receptor. Verekitug is currently being evaluated in two separate multi-national, placebo-controlled, randomized Phase 2 clinical trials, the VALIANT trial in patients with severe asthma (NCT06196879) and the VIBRANT trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) (NCT06164704). Upstream Bio is also initiating a Phase 2 clinical trial (NCT06981078) of verekitug in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).
In preclinical studies, verekitug demonstrated high occupancy of the TSLP receptor and potent inhibition of TSLP signaling. Additionally, verekitug inhibited cytokine production from both CD4+ T cells and ILC2 cells and completely suppressed skin allergic reactions in a non-human primate model, suggesting that it may be effective against multiple types of inflammation.
Three clinical trials have been completed for verekitug, including a Phase 1 single-ascending dose (SAD) clinical trial and a Phase 1b multiple-ascending dose (MAD) clinical trial. In these trials, verekitug was well tolerated, had no clinically meaningful immunogenicity, and showed a predictable and consistent pharmacokinetic profile and high subcutaneous bioavailability.
About Upstream Bio
Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is developing verekitug, the only known antagonist currently in clinical development that targets the receptor for thymic stromal lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. The Company has advanced this highly potent monoclonal antibody into separate Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and is initiating development in chronic obstructive pulmonary disease. Upstream Bio’s team is committed to maximizing verekitug’s unique attributes to address the substantial unmet needs for patients underserved by today’s standard of care. To learn more, please visit
www.upstreambio.com
.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “continue,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “predict,” “project,” “seeks,” “should,” “target,” “will” and variations of these words or similar expressions. Any statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, express or implied statements regarding: the global development of verekitug for the treatment of severe asthma, CRSwNP and COPD, including the initiation, timing, progress and results of ongoing and planned clinical trials; and expectations regarding the differentiation, safety, efficacy, tolerability, and/or extended dosing interval of verekitug. Any forward-looking statements in this press release are based on the Company’s current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Readers are cautioned that actual results, levels of activity, safety, efficacy, performance or events and circumstances could differ materially from those expressed or implied in the Company’s forward-looking statements due to a variety of risks and uncertainties, which include, without limitation, risks and uncertainties related to: Upstream Bio’s ability to advance verekitug through clinical development, and to obtain regulatory approval of and ultimately commercialize verekitug on the expected timeline, if at all; the initiation, timing, progress and results of clinical trials; Upstream Bio’s ability to fund its development activities and achieve development goals; Upstream Bio’s dependence on third parties to conduct clinical trials and manufacture verekitug, and commercialize verekitug, if approved; Upstream Bio’s ability to attract, hire and retain key personnel, and protect its intellectual property; Upstream Bio’s financial condition and need for substantial additional funds in order to complete development activities and commercialize verekitug, if approved; regulatory developments and approval processes of the U.S. Food and Drug Administration and comparable foreign regulatory authorities; Upstream Bio’s competitors and industry; and other risks and uncertainties described in greater detail under the caption “Risk Factors” in Upstream Bio’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, as well as any subsequent filings with the SEC. Any forward-looking statements represent Upstream Bio’s views only as of today and should not be relied upon as representing its views as of any subsequent date. Upstream Bio explicitly disclaims any obligation or undertaking to update any forward-looking statements contained herein to reflect any change in its expectations or any changes in events, conditions or circumstances on which any such statement is based except to the extent required by law, and claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
